Effect of folic acid in treatment of fatty liver disease

Not Applicable

• Conditions: on-alcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20190901044662N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Patients who are diagnosed to have non alcoholic fatty liver disease confirmed with ultrasonography result
Ages between 18-80 years
Serum alanine transaminase enzyme level higher than 30 U/L in men
Serum alanine transaminase enzyme level higher than 19 U/L in women

Exclusion Criteria

Pregnancy
Lactation
Alcohol consumption greater than 20 g per day
Having diseases such as hereditary hemochromatosis, Wilson's disease and a1 antitripsin enzyme deficiency
History of jejunoileal bypass surgery or gastroplasty
History of receiving total parenteral nutrition during last 6 months
Consumption of statins and hepatotoxic drugs such as calcium channel blocker, methotrexate, amiodarone, chloroquine
History of hypothyroidism and Cushing's syndrome
Intake of folate, B12, vitamin E and omega-3 supplements during the last 3 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of alanine transaminase. Timepoint: At baseline and 8 weeks after the start of the intervention. Method of measurement: Laboratory clinical kit and analyzer instrument.;Serum level of aspartate transaminase. Timepoint: At baseline and 8 weeks after the start of the intervention. Method of measurement: Laboratory clinical kit and analyzer instrument.;Insulin resistance. Timepoint: At baseline and 8 weeks after the start of the intervention. Method of measurement: By the formula of homeostatic model assessment.;The grade of fatty liver. Timepoint: At baseline and 8 weeks after the start of the intervention. Method of measurement: By using ultrasonography.